Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
Viatris collaboration revenue of $14.5 million , increased 39% versus Q1 2023, reflecting margin improvement Continued progress for ampreloxetine CYPRESS enrollment Virtual ampreloxetine KOL event scheduled for May 23, 2024 Q1 2024 ending cash balance of $100 million DUBLIN May 13, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2024. "Building on recent momentum, the Theravance commercial team again delivered a solid quarter of YUPELRI hospital sales execution in the first quarter, setting us on a path to contribute significantly to the product's overall growth in 2024", said Rick E Winningham, Chief Executive Officer . "We remain laser focused on YUPELRI growth and CYPRESS execution and are looking forward to sharing more about our progress and plans for ampreloxetine at a Key Opinion Leader-led virtual investor event scheduled for May 23 rd
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024PR Newswire
- Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary DiseasePR Newswire
- Theravance Biopharma, Inc. (NASDAQ: TBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.MarketBeat
- Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma to Participate in an Upcoming Investor ConferencePR Newswire
TBPH
Earnings
- 8/5/24 - Miss
TBPH
Sec Filings
- 10/24/24 - Form SC
- 9/23/24 - Form 8-K
- 9/10/24 - Form 8-K
- TBPH's page on the SEC website